Leap Therapeutics Inc
LPTX2.050USD
0.0000.00%
Cierre 02/06, 16:00（ET）Cotizaciones retrasadas 15 min
84.95MCap. mercado
PérdidaP/E TTM
Más Datos de Leap Therapeutics Inc Compañía
Leap Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways. The Company’s lead clinical stage drug candidate is sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1 (DKK1). DKK1 is also a modulator of CKAP4/PI3K/AKT signaling. The Company is developing DKN-01 in a clinical trial in patients with colorectal cancer and has also conducted clinical trials in patients with gastric/gastroesophageal junction cancer and endometrial cancer patients. The Company also has a preclinical program to develop a proprietary monoclonal antibody known as FL-501. FL-501 is a monoclonal antibody in preclinical development that targets growth and differentiation factor 15 (GDF15), which is a cytokine that is produced at elevated levels in response to various stresses.
Información de Leap Therapeutics Inc
Símbolo de cotizaciónLPTX
Nombre de la empresaCypherpunk Technologies Inc
Fecha de salida a bolsaJan 24, 2017
Director ejecutivoOnsi (Douglas E)
Número de empleados52
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 24
Dirección47 Thorndike Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal02142
Teléfono16172524343
Sitio Webhttps://www.leaptx.com/
Símbolo de cotizaciónLPTX
Fecha de salida a bolsaJan 24, 2017
Director ejecutivoOnsi (Douglas E)
Ejecutivos de Leap Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. William W. Li, M.D.
Dr. William W. Li, M.D.
Independent Director
Independent Director
--
--
Dr. Joseph Loscalzo, M.D., Ph.D.
Dr. Joseph Loscalzo, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Nissim Mashiach
Mr. Nissim Mashiach
Independent Director
Independent Director
--
--
Mr. Mark O'Mahony
Mr. Mark O'Mahony
Chief Manufacturing Officer
Chief Manufacturing Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Douglas E. (Doug) Onsi
Mr. Douglas E. (Doug) Onsi
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
141.58K
+712.00%
Dr. Christopher K. Mirabelli, Ph.D.
Dr. Christopher K. Mirabelli, Ph.D.
Director
Director
23.76K
+712.00%
Ms. Christine Granfield
Ms. Christine Granfield
Vice President, Head - Regulatory Affairs and Quality
Vice President, Head - Regulatory Affairs and Quality
15.90K
+15896.00%
Dr. Jason Baum, Ph.D.
Dr. Jason Baum, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
15.90K
+15896.00%
Dr. James H. Cavanaugh, Ph.D.
Dr. James H. Cavanaugh, Ph.D.
Independent Director
Independent Director
214.00
--
Dr. Thomas Dietz, Ph.D.
Dr. Thomas Dietz, Ph.D.
Lead Independent Director
Lead Independent Director
--
--
Desglose de ingresos
La empresa aún no ha revelado los datos relevantes.
La empresa aún no ha revelado los datos relevantes.
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: lun., 5 de ene
Actualizado: lun., 5 de ene
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
Otro
59.09%
Accionistas
Accionistas
Proporción
Winklevoss Capital Management, LLC
14.62%
Severns (Sean Michael)
10.59%
Gilead Sciences Inc
9.39%
The Vanguard Group, Inc.
3.75%
BofA Global Research (US)
2.55%
Otro
59.09%
Tipos de accionistas
Accionistas
Proporción
Family Office
14.62%
Corporation
11.53%
Individual Investor
11.07%
Investment Advisor
6.53%
Investment Advisor/Hedge Fund
3.10%
Research Firm
2.88%
Venture Capital
1.25%
Hedge Fund
0.35%
Bank and Trust
0.01%
Otro
48.65%
Participación institucional
Actualizado: jue., 1 de ene
Actualizado: jue., 1 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
109
9.04M
15.96%
-11.00M
2025Q3
109
9.06M
16.46%
-11.77M
2025Q2
120
18.70M
45.12%
-8.55M
2025Q1
140
18.85M
45.62%
-6.95M
2024Q4
134
21.35M
55.72%
-2.16M
2024Q3
140
20.83M
54.42%
+2.16M
2024Q2
141
20.87M
54.74%
+4.28M
2024Q1
149
9.36M
39.74%
-1.79M
2023Q4
154
7.72M
34.00%
-3.79M
2023Q3
169
9.36M
44.45%
-1.96M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Winklevoss Capital Management, LLC
8.28M
14.62%
+8.28M
--
Oct 24, 2025
Severns (Sean Michael)
6.00M
10.59%
+6.00M
--
Nov 12, 2025
Gilead Sciences Inc
5.32M
9.39%
--
--
Oct 24, 2025
The Vanguard Group, Inc.
1.16M
2.05%
--
--
Sep 30, 2025
BofA Global Research (US)
1.44M
2.55%
+1.44M
+451295.63%
Sep 30, 2025
Acadian Asset Management LLC
1.24M
2.18%
--
--
Sep 30, 2025
Beigene Ltd
1.22M
2.15%
+1.22M
--
Oct 31, 2024
Simplify Asset Management Inc
975.61K
1.72%
+118.25K
+13.79%
Sep 30, 2025
HealthCare Ventures LLC
676.32K
1.19%
-20.91K
-3.00%
Oct 24, 2025
Geode Capital Management, L.L.C.
312.19K
0.55%
--
--
Sep 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
Simplify Health Care ETF
0.37%
iShares Micro-Cap ETF
0%
Dimensional US Core Equity 1 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Avantis US Small Cap Equity ETF
0%
Simplify Health Care ETF
Proporción0.37%
iShares Micro-Cap ETF
Proporción0%
Dimensional US Core Equity 1 ETF
Proporción0%
DFA Dimensional US Sustainability Core 1 ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Fecha
Fecha ex-dividendo
Tipo
Relación
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
Jun 20, 2023
Merger
10→1
